CHD1 and prostate neoplasm: Recent cancer genomic studies identified recurrent mutations and deletions of the CHD1 gene in prostate tumors (8-10%), uterine (11%), melanoma (7%), and colorectal cancers (6%) (Figures 2A, B) (55, 56).